Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Slack     Google Drive     Print     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com


Here is a great video summarizing hemodynamic issues in airway management

Buscar en contenido


martes, 7 de junio de 2016


University of Texas - Houston
Emergency Medicine Literature of Note - June 6, 2016 - Posted by Ryan Radecki
"I am probably the last person to comment on ENCHANTED, the trial testing low-dose vs. standard-dose tPA in “Asians”. When it was released, to some fanfare in the New England Journal of Medicine, I had little to say – it is, frankly, a rather bland contribution to the science. What has been fascinating, however, is the unusually divergent interpretation of the results. To wit, the accompanying editorial in the NEJM states:
“ENCHANTED provides no compelling evidence for using low-dose alteplase 
for acute ischemic stroke in Asian or other populations on the basis of 
safety considerations or clinical outcomes.”
This is a relatively reasonable interpretation of the results – hinging on the word “compelling”. No one’s hearts are to be set a-flutter over these results, but that does a disservice to the ultimate clinical question of which dose is appropriate. The lay press, however, is here to clear things up – or is it?
The question, simply, comes down to how easily one interprets “non-inferiority” – a point made nicely by Rory Spiegel in his post..."